Roche asthma treatment performs well in Phase IIb trial


Roche's (RHHBY) Lebrikizumab injection significantly lowered the rate of asthma attacks and improved lung function in a Phase IIb trial of patients with a severe form of the condition.

In subjects with high levels of periostin, a protein that indicates a certain type of asthma and can be detected with a simple blood test, Lebrikizumab cut asthma attacks by 60% vs 5% for patients with a low level of the biomarker.

Roche has already started two Phase III studies of Lebrikizumab and plans to file for authorization in 2016. The company has identified it as a potential blockbuster. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs